SLC5A2 and hydrops fetalis: However, quite unexpectedly, the SGLT2 inhibitor can reduce major adverse cardiovascular events, including cardiovascular death, HF-related admission, and all-cause mortality, in recent trials (Zinman et al., 2015; Neal et al., 2017; McMurray et al., 2019; Wiviott et al., 2019).